title: [The IL-6 and COX-2 expression related to sensitivity of chemoradiotherapy and prognosis in esophageal carcinoma].
abstract: Chemoradiation therapy (CRT) for esophageal cancer induces inflammatory responses within tumor tissues. Inflammatory cells infiltrated into the tumor tissues may modulate the CRT responses via inflammation-related molecules such as IL-6 or COX-2. In the present study, we investigated a relationship between IL-6/COX-2 expression and CRT responses for esophageal cancer. A surgical resection following CRT was performed, and the specimens from the patients with cT3/T4 esophageal squamous cell examined for IL-6/COX-2 expression in both residual cancer and stromal cells by immunohistochemical staining. CRT responses were divided into responder group (Grade 1b and Grade 2) and non-responder group (Grade 1a). COX-2 in cancer cells and IL-6 in stromal cells were associated with non-responder and responder, respectively. In addition, IL-6 in stromal cells was significantly correlated with overall survival. Our data suggest that inflammatory responses concomitant with CRT responses could play a role in chemoradiation responses and prognosis.
authors.affiliation: Department of Surgery, Division of Digestive Surgery, Kyoto Prefectural University of Medicine.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Okamura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Kentaro
authors.initials: K
authors.lastname: Suchi
authors.forename: Hiroko
authors.initials: H
authors.lastname: Okamura
authors.forename: Seiji
authors.initials: S
authors.lastname: Umehara
authors.forename: Momoko
authors.initials: M
authors.lastname: Todo
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kuriu
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ikoma
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kubota
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Nakanishi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ichikawa
authors.forename: Shojiro
authors.initials: S
authors.lastname: Kikuchi
authors.forename: Kazuma
authors.initials: K
authors.lastname: Okamoto
authors.forename: Toshiya
authors.initials: T
authors.lastname: Ochiai
authors.forename: Chouhei
authors.initials: C
authors.lastname: Sakakura
authors.forename: Yukihito
authors.initials: Y
authors.lastname: Kokuba
authors.forename: Teruhisa
authors.initials: T
authors.lastname: Sonoyama
authors.forename: Eigo
authors.initials: E
authors.lastname: Otsuji
mesh_terms: D003131:Combined Modality Therapy; D051546:Cyclooxygenase 2 / Q000032:analysis*; D004938:Esophageal Neoplasms / Q000737:chemistry / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007150:Immunohistochemistry; D015850:Interleukin-6 / Q000032:analysis*; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D015850:Interleukin-6; D051546:Cyclooxygenase 2